OptiNose Inc. (NASDAQ:OPTN) shares traded -2.11% lower at $1.86 on Wall Street last session.
OPTN stock price is now 5.93% away from the 50-day moving average and -32.10% away from the 200-day moving average. The market capitalization of the company currently stands at $211.72M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
, while ‘Cowen’ rates the stock as ‘Outperform’.
In other news, Miller Peter K, Chief Executive Officer sold 29,664 shares of the company’s stock on Jan 13. The stock was sold for $52,505 at an average price of $1.77. Upon completion of the transaction, the Chief Executive Officer now directly owns 853,384 shares in the company, valued at $1.59 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 13, Chief Legal Officer & Corp Sec Marino Michael F III sold 5,241 shares of the business’s stock. A total of $9,277 was realized by selling the stock at an average price of $1.77. This leaves the insider owning 180,353 shares of the company worth $0.34 million. Insiders disposed of 313,106 shares of company stock worth roughly $0.58 million over the past 1 year. A total of 1.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OPTN stock. A new stake in OptiNose Inc. shares was purchased by MVM PARTNERS, LLC during the first quarter worth $27,166,000. GREAT POINT PARTNERS I LP invested $14,684,000 in shares of OPTN during the first quarter. In the first quarter, ARMISTICE CAPITAL, LLC acquired a new stake in OptiNose Inc. valued at approximately $3,713,000. NANTAHALA CAPITAL MANAGEMENT, LLC acquired a new stake in OPTN for approximately $2,697,000. CHEYNE CAPITAL MANAGEMENT (UK) LLP purchased a new stake in OPTN valued at around $734,000 in the second quarter. In total, there are 74 active investors with 74.80% ownership of the company’s stock.
OptiNose Inc. (NASDAQ: OPTN) opened at $1.8400 on Tuesday. During the past 12 months, OptiNose Inc. has had a low of $1.55 and a high of $4.30. The fifty day moving average price for OPTN is $1.7558 and a two-hundred day moving average price translates $2.7393 for the stock.
The latest earnings results from OptiNose Inc. (NASDAQ: OPTN) was released for Sep, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.18, inline with analysts’ expectations of -$0.18. This compares to -$0.32 EPS in the same period last year. The net profit margin was -96.60% and return on equity was 150.00% for OPTN. The company reported revenue of $20.08 million for the quarter, compared to $21.83 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -8.01 percent. For the current quarter, analysts expect OPTN to generate $20.67M in revenue.
OptiNose Inc.(OPTN) Company Profile
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
